top of page
Audio Overviews


Episode 8: Launching Lumara
Episode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignment across Access, HEOR, Medical, and Field.
Greg Johnsen
Nov 24, 20251 min read


Episode 7: Lessons from Elsewhere –– What Other TAs Are Doing Better
Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch.
Greg Johnsen
Nov 16, 20251 min read


Episode 6: The Unknown Unknowns
Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening, field feedback loops, KOL digital patterns, and payer advisory monitoring translate into real decisions.
Greg Johnsen
Nov 10, 20251 min read


Episode 5: Scaling the Access Wall
Episode 5 examines how real-world evidence (RWE) is now the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations.
Greg Johnsen
Nov 3, 20251 min read


Episode 4: Message Battles
In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible payer narrative — one that can cut through entrenched positioning and resonate with pharmacy and medical di
Greg Johnsen
Oct 27, 20252 min read


Lumara Series Episode 2: The Coverage Chessboard
Episode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers.
Greg Johnsen
Oct 13, 20251 min read


Lumara Series Episode 1: Meet Lumara
In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market.
Greg Johnsen
Oct 1, 20251 min read


Trailer: The Lumara Series
Series Overview: The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially...
Greg Johnsen
Sep 21, 20252 min read
bottom of page
